{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T18:46:27Z","timestamp":1789238787088,"version":"build-2803163510"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2017YFC1200503"],"award-info":[{"award-number":["2017YFC1200503"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular Immunology"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.cellimm.2020.104041","type":"journal-article","created":{"date-parts":[[2020,1,11]],"date-time":"2020-01-11T10:55:19Z","timestamp":1578740119000},"page":"104041","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":73,"special_numbering":"C","title":["Oncolytic adenovirus targeting TGF-\u03b2 enhances anti-tumor responses of mesothelin-targeted chimeric antigen receptor T cell therapy against breast cancer"],"prefix":"10.1016","volume":"348","author":[{"given":"Yuxiang","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengjun","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbo","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianxin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prem","family":"Seth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuefeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cellimm.2020.104041_b0005","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cellimm.2020.104041_b0010","doi-asserted-by":"crossref","first-page":"280ps7","DOI":"10.1126\/scitranslmed.aaa3643","article-title":"Adoptive cellular therapy: a race to the finish line","volume":"7","author":"June","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.cellimm.2020.104041_b0015","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cellimm.2020.104041_b0020","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ymthe.2016.10.020","article-title":"Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 Anti-CD19 CAR T cell therapy in refractory aggressive lymphoma","volume":"25","author":"Locke","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.cellimm.2020.104041_b0025","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1111\/cas.13239","article-title":"Clinical development of anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma","volume":"108","author":"Makita","year":"2017","journal-title":"Cancer Sci."},{"key":"10.1016\/j.cellimm.2020.104041_b0030","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41591-019-0421-7","article-title":"A safe and potent anti-CD19 CAR T cell therapy","volume":"25","author":"Ying","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.cellimm.2020.104041_b0035","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/CJI.0000000000000263","article-title":"Generation of a transgenic BALB\/c mouse line with selective expression of human mesothelin in thyroid gland: application in mesothelin-targeted immunotherapy","volume":"42","author":"Bera","year":"2019","journal-title":"J. Immunother."},{"key":"10.1016\/j.cellimm.2020.104041_b0040","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1158\/1535-7163.MCT-13-0926","article-title":"Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect","volume":"13","author":"Golfier","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.cellimm.2020.104041_b0045","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.1158\/1078-0432.CCR-03-0801","article-title":"Mesothelin: a new target for immunotherapy","volume":"10","author":"Hassan","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cellimm.2020.104041_b0050","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ejca.2007.08.028","article-title":"Mesothelin targeted cancer immunotherapy","volume":"44","author":"Hassan","year":"2008","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.cellimm.2020.104041_b0055","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1590\/0001-3765201620150107","article-title":"Mesothelin as a biomarker for ovarian carcinoma: a meta-analysis","volume":"88","author":"Madeira","year":"2016","journal-title":"An. Acad. Bras. Cienc."},{"key":"10.1016\/j.cellimm.2020.104041_b0060","doi-asserted-by":"crossref","first-page":"34103","DOI":"10.18632\/oncotarget.26135","article-title":"Anetumab ravtansine inhibits tumor growth and shows additive effect in combination with targeted agents and chemotherapy in mesothelin-expressing human ovarian cancer models","volume":"9","author":"Quanz","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.cellimm.2020.104041_b0065","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1200\/JCO.2016.68.3672","article-title":"Mesothelin Immunotherapy for Cancer: ready for prime time?","volume":"34","author":"Hassan","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cellimm.2020.104041_b0070","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.omto.2019.03.001","article-title":"Oncolytic virus-based cytokine expression to improve immune activity in brain and solid tumors","volume":"13","author":"Pearl","year":"2019","journal-title":"Mol. Ther. Oncol."},{"key":"10.1016\/j.cellimm.2020.104041_b0075","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1089\/hum.2010.018","article-title":"Systemic delivery of an oncolytic adenovirus expressing soluble transforming growth factor-beta receptor II-Fc fusion protein can inhibit breast cancer bone metastasis in a mouse model","volume":"21","author":"Hu","year":"2010","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.cellimm.2020.104041_b0080","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/cgt.2009.72","article-title":"A modified hTERT promoter-directed oncolytic adenovirus replication with concurrent inhibition of TGFbeta signaling for breast cancer therapy","volume":"17","author":"Hu","year":"2010","journal-title":"Cancer Gene Ther."},{"issue":"19","key":"10.1016\/j.cellimm.2020.104041_b0085","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/cgt.2012.41","article-title":"Intravenous administration of adenoviruses targeting transforming growth factor beta signaling inhibits established bone metastases in 4T1 mouse mammary tumor model in an immunocompetent syngeneic host","volume":"2012","author":"Zhang","year":"2012","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.cellimm.2020.104041_b0090","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/mt.2014.80","article-title":"Ad5\/48 hexon oncolytic virus expressing sTGFbetaRIIFc produces reduced hepatic and systemic toxicities and inhibits prostate cancer bone metastases","volume":"22","author":"Xu","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.cellimm.2020.104041_b0095","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1089\/hum.2012.040","article-title":"Systemic delivery of oncolytic adenoviruses targeting transforming growth factor-beta inhibits established bone metastasis in a prostate cancer mouse model","volume":"23","author":"Hu","year":"2012","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.cellimm.2020.104041_b0100","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1089\/hum.2019.059","article-title":"An oncolytic adenovirus targeting transforming growth factor beta inhibits protumorigenic signals and produces immune activation: a novel approach to enhance anti-PD-1 and anti-CTLA-4 therapy","volume":"30","author":"Yang","year":"2019","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.cellimm.2020.104041_b0105","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.cellimm.2018.05.004","article-title":"A novel AXL chimeric antigen receptor endows T cells with anti-tumor effects against triple negative breast cancers","volume":"331","author":"Wei","year":"2018","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.cellimm.2020.104041_b0110","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1159\/000489979","article-title":"Novel therapeutic strategies for solid tumor based on body's intrinsic antitumor immune system","volume":"47","author":"Duan","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.cellimm.2020.104041_b0115","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/bs.acr.2015.04.002","article-title":"Myeloid-derived suppressor cells: critical cells driving immune suppression in the tumor microenvironment","volume":"128","author":"Parker","year":"2015","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.cellimm.2020.104041_b0120","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/s41598-017-00462-8","article-title":"CRISPR\/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells","volume":"7","author":"Rupp","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cellimm.2020.104041_b0125","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00262-018-2281-2","article-title":"CRISPR\/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions","volume":"68","author":"Hu","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.cellimm.2020.104041_b0130","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.omto.2018.08.002","article-title":"Checkpoint blockade reverses anergy in IL-13Ralpha2 humanized scFv-Based CAR T cells to treat murine and canine gliomas","volume":"11","author":"Yin","year":"2018","journal-title":"Mol. Ther. Oncolytics."},{"key":"10.1016\/j.cellimm.2020.104041_b0135","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1158\/2159-8290.CD-NB2015-158","article-title":"First oncolytic viral therapy for melanoma","volume":"6","author":"Poh","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cellimm.2020.104041_b0140","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40265-015-0522-7","article-title":"Talimogene laherparepvec: first global approval","volume":"76","author":"Greig","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.cellimm.2020.104041_b0145","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2217\/imt.15.116","article-title":"Interview with Robert Coffin, inventor of T-VEC: the first oncolytic immunotherapy approved for the treatment of cancer","volume":"8","author":"Coffin","year":"2016","journal-title":"Immunotherapy"},{"key":"10.1016\/j.cellimm.2020.104041_b0150","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1115641","article-title":"First oncolytic virus approved for melanoma immunotherapy","volume":"5","author":"Pol","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.cellimm.2020.104041_b0155","doi-asserted-by":"crossref","DOI":"10.4161\/21505594.2014.988098","article-title":"Oncolytic virus expressing RANTES and IL-15 enhances function of CAR-modified T cells in solid tumors","volume":"4","author":"Nishio","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.cellimm.2020.104041_b0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1003251","article-title":"Inflammation-mediated genetic and epigenetic alterations drive cancer development in the neighboring epithelium upon stromal abrogation of TGF-\u03b2 signaling","volume":"9","author":"Achyut","year":"2013","journal-title":"PLoS Genet."},{"key":"10.1016\/j.cellimm.2020.104041_b0165","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1038\/s41375-019-0448-2","article-title":"Transforming growth factor (TGF)-\u03b2 pathway as a therapeutic target in lower risk myelodysplastic syndromes","volume":"33","author":"Bewersdorf","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.cellimm.2020.104041_b0170","first-page":"1","article-title":"Transforming growth factor-\u03b2 in the acute kidney injury to chronic kidney disease transition","volume":"30","author":"Gewin","year":"2019","journal-title":"Nephron"},{"key":"10.1016\/j.cellimm.2020.104041_b0175","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/mc.22005","article-title":"Apigenin inhibits TGF-beta-induced VEGF expression in human prostate carcinoma cells via a Smad2\/3- and Src-dependent mechanism","volume":"53","author":"Mirzoeva","year":"2014","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.cellimm.2020.104041_b0180","first-page":"1","article-title":"TGF-beta\/PI3K\/AKT\/mTOR\/NF-kB pathway. Clinicopathological features in prostate cancer","volume":"11","author":"Torrealba","year":"2019","journal-title":"Aging Male"},{"key":"10.1016\/j.cellimm.2020.104041_b0185","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3390\/molecules24010144","article-title":"Structure identification of viceninii extracted from dendrobium officinale and the reversal of TGF-beta1-induced epithelial(-) mesenchymal transition in lung adenocarcinoma cells through TGF-beta\/Smad and PI3K\/Akt\/mTOR signaling pathways","volume":"24","author":"Luo","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.cellimm.2020.104041_b0190","first-page":"680","article-title":"Transforming growth factor beta regulates hepatic progenitor cells migration via PI3K\/AKT\/mTOR\/p70S6K pathway","volume":"26","author":"Pu","year":"2018","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"10.1016\/j.cellimm.2020.104041_b0195","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.3390\/ijms19061556","article-title":"Isoviolanthin extracted from dendrobium officinale reverses TGF-beta1-mediated epithelial(-) mesenchymal transition in hepatocellular carcinoma cells via deactivating the TGF-beta\/smad and PI3K\/Akt\/mTOR signaling pathways","volume":"19","author":"Xing","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cellimm.2020.104041_b0200","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/s41580-018-0007-0","article-title":"Contextual determinants of TGF\u03b2 action in development, immunity and cancer","volume":"19","author":"David","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."}],"container-title":["Cellular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008874919304599?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008874919304599?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T23:01:52Z","timestamp":1757804512000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008874919304599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":40,"alternative-id":["S0008874919304599"],"URL":"https:\/\/doi.org\/10.1016\/j.cellimm.2020.104041","relation":{},"ISSN":["0008-8749"],"issn-type":[{"value":"0008-8749","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oncolytic adenovirus targeting TGF-\u03b2 enhances anti-tumor responses of mesothelin-targeted chimeric antigen receptor T cell therapy against breast cancer","name":"articletitle","label":"Article Title"},{"value":"Cellular Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cellimm.2020.104041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104041"}}